Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Metabolism of [14C]PF-07321332 (Nirmatrelvir) in Healthy Males
NCT05178654Phase 1Withdrawn
- Sponsor
- Pfizer
- Start
- Feb 2022
- Primary completion
- Apr 2022
- Modality
- Orthosteric Ligands
01
Overview
Phase 1, open-label, single-arm trial of Nirmatrelvir in coronavirus disease 2019 (COVID-19), sponsored by Pfizer. Primary endpoints: Cumulative amount of radioactivity Recovered in Urine (Ae), Cumulative amount of radioactivity Recovered in Feces (Ae) and 3 more. Planned start Feb 2022; status: withdrawn.
02
Drugs
Nirmatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05178654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05178654.